Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Collaboration partner Gilead Sciences provided $20m as the cancer therapy researcher extended its overall equity funding to $165m.

Lloyds and Nationwide Building Society contributed to a round that pushed the payment software provider's overall funding to $51m.

Growth equity firm Greyhound Capital has received backing from Rabobank's Rabo Frontier Ventures vehicle as it raises its second fund.

The gig worker-focused mobile wallet developer tested its technology within Cabify before reeling the corporate in for a $12.5m round.

Mitsubishi UFJ Lease & Finance and Fuyo General Lease are among the limited partners for the unit's third fund, following its opening of an office in Japan.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Eberhard Karls University of Tübingen's messenger RNA drug developer CureVac priced the offering at the top of its range.

GlaxoSmithKline Eli Lilly and Genmab-backed messenger RNA drug developer CureVac priced the offering at the top of its range.

The fungal disease drug developer pulled in $60.8m from investors including Novo, which is switching board members at the company.